New York State Common Retirement Fund reduced its holdings in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 0.0% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,300 shares of the specialty pharmaceutical company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned 0.10% of SciClone Pharmaceuticals worth $564,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Louisiana State Employees Retirement System increased its stake in SciClone Pharmaceuticals by 0.5% in the 2nd quarter. Louisiana State Employees Retirement System now owns 21,100 shares of the specialty pharmaceutical company’s stock worth $232,000 after acquiring an additional 100 shares during the last quarter. Arizona State Retirement System increased its stake in SciClone Pharmaceuticals by 0.7% in the 2nd quarter. Arizona State Retirement System now owns 27,000 shares of the specialty pharmaceutical company’s stock worth $297,000 after acquiring an additional 200 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in SciClone Pharmaceuticals by 2.7% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock worth $114,000 after acquiring an additional 310 shares during the last quarter. Texas Permanent School Fund increased its stake in SciClone Pharmaceuticals by 1.3% in the 2nd quarter. Texas Permanent School Fund now owns 37,770 shares of the specialty pharmaceutical company’s stock worth $415,000 after acquiring an additional 502 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in SciClone Pharmaceuticals by 0.3% in the 2nd quarter. Principal Financial Group Inc. now owns 403,714 shares of the specialty pharmaceutical company’s stock worth $4,441,000 after acquiring an additional 1,214 shares during the last quarter. Institutional investors and hedge funds own 72.80% of the company’s stock.

In other news, VP Lan Xie sold 10,000 shares of the stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total transaction of $110,000.00. Following the transaction, the vice president now directly owns 10,000 shares in the company, valued at approximately $110,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Hong Zhao sold 30,000 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $330,000.00. Following the transaction, the chief executive officer now owns 30,000 shares in the company, valued at $330,000. The disclosure for this sale can be found here. 5.16% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “SciClone Pharmaceuticals, Inc. (SCLN) Shares Sold by New York State Common Retirement Fund” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/12/sciclone-pharmaceuticals-inc-scln-shares-sold-by-new-york-state-common-retirement-fund.html.

SciClone Pharmaceuticals, Inc. (NASDAQ SCLN) opened at $11.15 on Friday. SciClone Pharmaceuticals, Inc. has a one year low of $8.55 and a one year high of $11.43.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. The business had revenue of $44.52 million for the quarter. SciClone Pharmaceuticals had a return on equity of 20.24% and a net margin of 27.39%.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.